Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting:a pilot study

作     者：Si-Man Zhu Wen-Hui Wang Jin-Zhu Guo Xin Guan Yue-Hua Men Hua Zhang Yi-Ming Zhao Chun-Lei Zhang Zhu Si-Man;Wang Wen-Hui;Guo Jin-Zhu;Guan Xin;Men Yue-Hua;Zhang Hua;Zhao Yi-Ming;Zhang Chun-Lei

作者机构：Department of DermatologyPeking University Third HospitalBeijing 100191China Research Center of Clinical EpidemiologyPeking University Third HospitalBeijing 100191China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2020年第133卷第24期

页      面：3017-3019页

核心收录：

学科分类：1002[医学-临床医学] 100206[医学-皮肤病与性病学] 10[医学] 

基　　金：National Natural Science Foundation of China(No.81972560) Beijing Municipal Natural Science Foundation(No.7202231) 

主　　题：psoriasis clinical summarized 

摘      要：To the Editor:Psoriasis is a chronic,recurrent,systemic,immune-mediated inflammatory disease that mainly affects the skin,nails,and *** psoriasis is the most common type of psoriasis,accounting for more than 80%to 90%of all ***,a human IgG monoclonal antibody that antagonizes interleukin 17A(IL-17A),was approved by the US Food and Drug Administration in 2015 to treat moderate-to-severe plaque psoriasis.A Chinese multicenter,double-blind,placebo-controlled phase III randomized clinical trial(RCT)demonstrated excellent efficacy and safety.[1]Secukinumab has been available on the Chinese market since May 2019,with a recommended dose of 300 *** is well-known that RCTs,due to their rigorous,normalized design schemes,cannot fully reflect what happens in clinical practice *** concept of theefficacy-effectiveness gapwas also introduced,[2]which supports the importance of real-world ***,we retrospectively summarized all the inpatients with plaque psoriasis who were treated with secukinumab at Peking University Third Hospital from June to December *** information(sex,age,weight,body mass index,etc.)and clinical features(disease duration,family history,comorbidities,laboratory tests,previous treatments,concomitant treatments,etc.)were collected from clinical *** psoriasis area severity index(PASI),body surface area(BSA),dermatology life quality index(DLQI),psoriasis scalp severity index(PSSI),nail psoriasis severity index(NAPSI),and palmoplantar psoriasis area and severity index(ppPASI)were also recorded.